1887

Abstract

Real-world data regarding the effectiveness, safety and immunogenicity of the Pfizer-BioNTech BNT162b2 mRNA vaccine are accumulating in the literature, suggesting that this vaccine generates high titres of S1-binding IgG antibodies that exhibit potent virus neutralization capacity. This is the first phase IV immunogenicity study to recruit a large number of Greek healthcare workers (=425) including 63 previously-infected subjects. We measured titres of neutralizing IgGs against the receptor-binding domain of the S1 subunit of the spike protein of SARS-CoV-2 14 days post-immunization with the first dose, employing the SARS-CoV-2 IgG II Quant assay. A total of 92.24 % of our study cohort received a positive assay outcome and titres varied with age. Post-hoc analysis revealed that although titres did not significantly differ among participants aged 20–49 years, a significant decline was marked in the age group of 50–59 years, which was further accentuated in subjects aged over 60. Antibody titres escalated significantly among the previously-infected, indicating the potential booster effect of the first dose in that group.

  • This is an open-access article distributed under the terms of the Creative Commons Attribution NonCommercial License. The Microbiology Society waived the open access fees for this article.
Loading

Article metrics loading...

/content/journal/jmm/10.1099/jmm.0.001387
2021-08-16
2022-09-28
Loading full text...

Full text loading...

/deliver/fulltext/jmm/70/8/jmm001387.html?itemId=/content/journal/jmm/10.1099/jmm.0.001387&mimeType=html&fmt=ahah

References

  1. Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N Engl J Med 2020; 383:2603–2615 [View Article] [PubMed]
    [Google Scholar]
  2. Dagan N, Barda N, Kepten E, Miron O, Perchik S et al. BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Mass Vaccination Setting. N Engl J Med 2021; 384:1412–1423 [View Article] [PubMed]
    [Google Scholar]
  3. Walsh EE, Frenck RW, Falsey AR, Kitchin N, Absalon J et al. Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates. N Engl J Med 2020; 383:2439–2450 [View Article] [PubMed]
    [Google Scholar]
  4. Sahin U, Muik A, Vogler I, Derhovanessian E, Kranz LM et al. BNT162b2 induces SARS-CoV-2-neutralising antibodies and T cells in humans. medRxiv 2020
    [Google Scholar]
  5. Abu Jabal K, Ben-Amram H, Beiruti K, Batheesh Y, Sussan C et al. Impact of age, ethnicity, sex and prior infection status on immunogenicity following a single dose of the BNT162b2 mRNA COVID-19 vaccine: real-world evidence from healthcare workers, Israel, December 2020 to January 2021. Eurosurveillance 2021; 26:2100096
    [Google Scholar]
  6. Samanovic MI, Cornelius AR, Wilson JP, Karmacharya T, Gray-Gaillard SL et al. Poor antigen-specific responses to the second BNT162b2 mRNA vaccine dose in SARS-CoV-2-experienced individuals. medRxiv [Internet] 2021
    [Google Scholar]
  7. Krammer F, Srivastava K, Team P, Simon V, Alshammary H et al. Robust spike antibody responses and increased reactogenicity in seropositive individuals after a 1 single dose of SARS-COV-2 mRNA vaccine 2 3. medRXiv 2015
    [Google Scholar]
  8. Pardi N, Hogan MJ, Naradikian MS, Parkhouse K, Cain DW et al. Nucleoside-modified mRNA vaccines induce potent T follicular helper and germinal center B cell responses. J Exp Med 2018; 215:1571
    [Google Scholar]
  9. Rauch S, Jasny E, Schmidt KE, Petsch B. New vaccine technologies to combat outbreak situations. Front Immunol 2018; 9:1963 [View Article]
    [Google Scholar]
  10. Wrapp D, Wang N, Corbett KS, Goldsmith JA, Hsieh CL et al. Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation. bioRxiv 2020
    [Google Scholar]
  11. SARS-CoV-2 Immunoassay Abbott core laboratory (Internet; 2021 https://www.corelaboratory.abbott/int/en/offerings/segments/infectious-disease/sars-cov-2
http://instance.metastore.ingenta.com/content/journal/jmm/10.1099/jmm.0.001387
Loading
/content/journal/jmm/10.1099/jmm.0.001387
Loading

Data & Media loading...

Most cited this month Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error